Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous fosfomycin for hospitalized adults with complicated urinary tract infection due to third-generation cephalosporin-resistant Enterobacterales
2024-516591-15-00Phase 4Authorised
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of fosfomycin in complicated urinary tract infection (cUTI) (2 arms), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Clinical response at test of cure. Planned start Nov 2024; status: authorised.
02
Drugs
fosfomycin
03
Conditions
complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on 2024-516591-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516591-15-00.